Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens.
In order to potentiate the low immunogenicity of the inactivated Newcastle disease virus immunized into chickens by mucosal route, liposomes as a drug delivery system and LPS (lipopolysaccharide) as an immuno-stimulator were evaluated. Here, we report a new nasal delivery system of inactivated Newcastle disease virus (NDV) vaccine. The intranasal vaccine was based on different lipids to form MLV (multi-lamellar vehicles) liposomes. The liposomes had combined carrier and adjuvant activities, which induced strong systemic (serum) and local (lung and nasal) humoral responses in SPF (specific-pathogen-free) chickens, and provided protective immunity. PC-Lip (phosphatidylcholine-liposome) elicited significant mucosal secretary immunoglobulin A (s-IgA) levels (p<0.05) in tracheal lavage fluid and serum IgG levels (p<0.05). In response to virulent viral challenge, birds treated with PBS (phosphate buffered saline) as control group died, whereas 80% of chickens which received PC-Lip, PC-Lip-LPS, PS-Lip (phosphatidylserine-liposome), and PS-Lip-LPS survived. HAI titers were 1:2560 in the PS-Lip-LPS group and 1:1280 in the PC-Lip, PC-Lip-LPS, and PS-Lip groups after two vaccinations. The results suggest that PC-Lip or PS-Lip might thus be suitable as a potential adjuvant for mucosal vaccination against NDV in chickens.
Tseng
Li-Ping
LP
Graduate Institute of Biomedical Engineering, College of Engineering, College of Medicine, National Taiwan University, Taiwan, Republic of China.
Chiou
Chwei-Jang
CJ
Chen
Chien-Chung
CC
Deng
Ming-Chung
MC
Chung
Tze-Wen
TW
Huang
Yi-You
YY
Liu
Der-Zen
DZ
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D002645:Chickens / Q000276:immunology*; D016503:Drug Delivery Systems; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000097:blood; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008081:Liposomes; D009521:Newcastle Disease / Q000276:immunology / Q000517:prevention & control; D009522:Newcastle disease virus / Q000276:immunology*; D013047:Specific Pathogen-Free Organisms; D014132:Trachea / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D008081:Liposomes; D015164:Vaccines, Inactivated; D014765:Viral Vaccines